IFN-β liquid formulations

Details IFN-β liquid formulations IFN-β liquid formulations

2005-02-08

2005-02-08

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C530S351000, C514S012200, C215S014000, C215S049000

Reexamination Certificate

active

06852314

ABSTRACT:
Interferon-β liquid formulations stabilized with a polyol, a non-reducing sugar or an amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-β is preferably recombinant.

REFERENCES:
patent: 4465622 (1984-08-01), Nobuhara et al.
patent: 4647454 (1987-03-01), Cymbalista et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5643566 (1997-07-01), Hanisch et al.
patent: 89245 (1983-08-01), None
patent: 270799 (1988-06-01), None
patent: 8902750 (1989-04-01), None
patent: 8904177 (1989-05-01), None
Dialog Information Services, file 351, WPIL, Dialog accession no. 003925794, WPI accession no. 84-071338/12, Toray Ind Inc: “Stabilising beta-interferon having no sugar chain by adding polyol, e.g. ethylene glycol, glycerine or sugar, esp. oligo saccharide”, JP 59025333, A, 840209, 8412 (Basic) Feb. 9, 1986.

Affiliated with

Also associated with

Rating

IFN-β liquid formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IFN-β liquid formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IFN-β liquid formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3476565